Vitiligo Pathogenesis: How Autoimmunity Targets the Melanocyte

This episode, "Vitiligo Pathogenesis: How Autoimmunity Targets the Melanocyte," has Dr. Hamzavi walking through the immunology that drives vitiligo.

Dr. Hamzavi frames vitiligo's pathogenesis as autoimmunity aimed at a target, the melanocyte, that cannot repair itself the way keratinocytes do. Oxidative stress initiates the process in genetically predisposed individuals, activating the innate immune system and ultimately switching on CD8-positive T cells, the effector cells that destroy melanocytes. He explains that these T cells are activated within an interferon-gamma-rich environment, where keratinocytes and fibroblasts secrete JAK-STAT-driven cytokines that recruit still more CD8-positive cells to the skin. Once this initial attack subsides, memory T cells sustained through IL-15 signaling perpetuate the cycle, which is why the disease can persist and recur long after an initial flare. Dr. Hamzavi describes the resulting challenge as a wound-healing problem layered on top of an immune one, since melanocytes are neural-crest-derived cells that regenerate slowly even once inflammation is controlled.

Dr. Taylor asks about the broader autoimmune landscape linked to vitiligo, and Dr. Hamzavi walks through the data. Between 10% and 20% of patients develop hypothyroidism within ten years of diagnosis, and registry and clinical-trial data show elevated rates of type 1 diabetes, pernicious anemia, small-intestinal colitis, autoimmune hearing loss, and myasthenia gravis compared with the general population. He notes these associations occur less frequently than thyroid disease but still well above baseline. Genome-wide association studies reinforce the clinical pattern, showing that the genes activated in vitiligo cluster in both immune-regulation and melanocyte-biology pathways. Dr. Hamzavi concludes that this genetic overlap, built on years of registry and trial work, leaves little doubt that vitiligo is fundamentally an autoimmune disease rather than a localized pigment disorder, a distinction he argues should shape how clinicians screen for and manage comorbid conditions going forward.

Up next, in "Diagnosing Vitiligo: Physical Exam, Labs, and When to Biopsy," the panel shifts to the exam room, covering the physical and laboratory workup for a new vitiligo diagnosis.

This video was supported independently by Pfizer.